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Abstract
Introduction The gut is often considered as the motor of critical
illness through bacterial translocation, which amplifies the
inflammatory response and alters the immune status. However,
systemic bacterial translocation was rarely proven and
endotoxin measurement only reflects translocation of Gram-
negative-derived products. The process could be more
frequently identified if peptidoglycan, derived from both Gram-
negative and Gram-positive bacteria, was measured.
Methods We developed a new tool to detect circulating
peptidoglycan-like structure using a NOD2-transfected cell line.
We also measured plasma and cell-associated endotoxin and
different plasma markers of inflammation. We studied 21
patients undergoing abdominal aortic surgery (AAS), and 21
patients undergoing carotid artery surgery (CAS) were included
as negative controls. Patients were sampled during surgery until
two days post-surgery.
Results In 90.5% of the AAS patients, a NOD2 agonist peak
was detected in plasma before aortic clamping, but after gut
manipulation by the surgeon, and persisted after blood
reperfusion. As expected, no peak was detected in plasma from
CAS patients (P  = 0.003). Leukocyte-bound endotoxin
appeared after blood reperfusion in 71% of the AAS patients,
and circulating endotoxin was detected for 57% of them. The
levels of interleukin (IL)-6, IL-10 and of inflammatory markers (C-
reactive protein, procalcitonin) were maximal at postoperative
day 1 or 2 in AAS patients. The levels of circulating NOD2
agonist positively correlated with those of cortisol and IL-10.
Conclusions The measurement of circulating NOD2 agonist
gives a higher informative tool than that of circulating endotoxin
for early and sensitive detection of the translocation of bacterial
products. The data suggest that circulating NOD2 agonist
contributes to further enhance the stress response following
surgery.
Introduction
The gut has often been claimed to be the motor of critical ill-
ness [1]. Translocation of microbial products has been
reported in different clinical settings such as in patients with
pancreatitis [2], cirrhosis [3], edema secondary to congestive
heart failure [4], chronic HIV infection [5], after cardio-pulmo-
nary bypass [6], after hemorrhagic shock [7], in patients resus-
citated after cardiac arrest [8], and after abdominal aortic
surgery [9].
Endotoxin (lipopolysaccharide (LPS)) is a microbial product
commonly measured in the bloodstream, and its levels corre-
late with survival in patients with sepsis [10]. Levels of circu-
lating endotoxin were also shown to correlate with liver
function deterioration in patients with cirrhosis [11] or with the
occurrence of multiorgan failure in intensive care unit patients
[12]. Although the occurrence of endotoxinemia is more fre-
quent than positive hemocultures, endotoxin being present
only in Gram-negative bacteria, its measurement does not
reflect the translocation of Gram-positive bacteria-derived
AAS: abdominal aortic surgery; CAS: carotid artery surgery; CRP: C-reactive protein; ELISA: enzyme linked immunosorbent assay; fsNOD2: a 
frameshift mutant of NOD2; HEK: human embryonic kidney; IL: interleukin; LAL: limulus amebocyte lysate; LPS: lipopolysaccharide; MDP: muramyld-
ipeptide; NF: nuclear factor; NOD: nucleotide-binding oligomerization domain; PAMPs: pathogen-associated molecular patterns; PBMC: peripheral 
blood mononuclear cells; PCT: procalcitonin; PGN: peptidoglycan; POD: postoperative day; SD: standard deviation; SEM: standard error of the 
mean; SIRS: systemic inflammatory response syndrome; TNF: tumor necrosis factor.Critical Care    Vol 13 No 4    Kim et al.
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compounds [13]. Furthermore, the measurement of LPS in
plasma is difficult because of the presence of many interfering
molecules such as soluble CD14, LPS-binding protein, and
high-density lipoproteins [14-16]. LPS may also be trapped by
circulating cells carrying receptors for LPS, such as mono-
cytes. For example, during meningococcal infection, leuko-
cyte-bound LPS was found in all studied patients, whereas
circulating endotoxin was detected in only two out of five
patients [17].
On the other hand, peptidoglycan (PGN) is a component of
both Gram-positive and Gram-negative bacterial cell walls and
its levels in plasma may better reflect bacterial translocation,
as found in 10 patients undergoing cardio-pulmonary bypass
[18]. However, the assay used in this study was not specific
for bacterial products and also measured fungal components
such as -glucan. Recent studies reported that PGN and its
fragments are recognized by intracellular pattern-recognition
molecules, members of the nucleotide-binding oligomerization
domain (NOD) family [19]. In particular, NOD2 recognizes a
PGN motif present on both Gram-positive and Gram-negative
bacteria. This sensing initiates an intracellular cascade that
leads to the activation of the nuclear transcription factor NF-
B and an inflammatory process [20,21]. Using this informa-
tion, we developed a new tool to detect circulating PGN-like
structures using a NOD2-transfected cell line and the luci-
ferase reporter gene [22].
Vascular surgery like all other surgery is associated with an
inflammatory process and an alteration of the immune status
that may favor the occurrence of nosocomial infections [23-
26]. Endotoxin translocation was previously reported in some
patients after abdominal aortic surgery (AAS), associated with
manipulation of the gut and aortic clamping [9], leading to a
significant decrease in mesenteric blood flow and the subse-
quent alteration of oxygen delivery to the intestinal epithelial
carriers [27,28]. The translocation could further amplify the
inflammatory response and alter the immune status, and may
contribute to the development of postoperative complications
[29-32]. Therefore, we aimed to detect circulating NOD2 ago-
nist in AAS patients susceptible to bacterial translocation, to
determine its frequency and its kinetics. Patients undergoing
carotid artery surgery (CAS) were included as a control group.
In addition, we analyze leukocyte-bound LPS, and measured
C-reactive protein (CRP), procalcitonin (PCT) and cortisol, as
well as several pro- and anti-inflammatory cytokines to assess
the level of systemic inflammation in the two groups of
patients.
Materials and methods
Subjects and operation
After approval of the study by the Ethics Committee for Human
Research of Pitié-Salpêtrière Hospital (Session of 4 April,
2007), patients scheduled for AAS were included in this pro-
spective observational study from June 2007 to April 2008 (n
= 21). As a control group, patients scheduled for CAS were
also included (n = 21). Excluded from the study were patients:
undergoing celoscopic surgery or surgery on the thoracic
aorta, with signs of pre-operative infection, undergoing
chronic dialysis, under anti-inflammatory medication or antibi-
otics treatment before surgery, presenting with on-going or
neoplasic hematologic pathology, and who were immunosup-
pressed. All patients gave informed consent. The protocol fol-
lowed for preoperative medication and anesthesia was similar
in both groups of patients. The only difference was that treat-
ment with anti-platelet aggregation agents was discontinued
five days before surgery for AAS patients, whereas it was con-
tinued until the day of surgery for CAS patients.
Usual premedication was maintained except for angiotensin-
converting enzyme inhibitors and angiotensin II antagonists,
which were discontinued the day before surgery. All patients
were premedicated with midazolam 5 mg given orally one hour
before surgery. During the operative period, all patients were
anesthetized by target-controlled infusion of propofol, sufen-
tanil, and cisatracurium. Antibioprophylaxis was performed
using cefamandole. Depending on hemodynamics and hema-
tocrit, fluid loading was performed using crystalloid infusion
(Ringer's lactate or isotonic saline) and colloid infusion
(hydroxyethylstach 130/0.4), associated with blood transfu-
sion, if necessary, to maintain a hemoglobin level above 10 g/
dl. Approximately 30 minutes before the end of surgery, all
patients received paracetamol for postoperative analgesia,
and in recovery room received intravenous morphine until pain
relief was achieved.
Blood sampling
Blood samples were collected into the sodium citrated vac-
uum tubes as follows: immediately before anesthesia induc-
tion (T1); before incision (T2), before aortic clamping (AAS
patients) or carotid artery clamping (CAS patients; T3) and
after blood reperfusion (T4) during the surgery, and on postop-
erative day one (POD1) and two (POD2) after the surgery.
One 5 ml tube was immediately centrifuged and plasma sam-
ples were stored at -80°C until assayed (within two months).
Another 5 ml tube was used for the analysis of leukocyte-
bound LPS.
Isolation of peripheral blood mononuclear cells from 
whole blood
For measurement of endotoxin associated with circulating leu-
kocytes, peripheral blood mononuclear cells (PBMC) were
isolated from whole blood after dilution 1:1 with RPMI-1640
(Lonza, Verviers, Belgium) and centrifugation (680 g, 15°C for
20 minutes) on Ficoll-Hypaque (Eurobio, Les Ulis, France).
After centrifugation, the cells at the medium/Ficoll interface
were collected, washed with RPMI-1640 and centrifuged
(350 g, 10°C for five minutes). The pellet was resuspended
with sterile endotoxin-free saline (0.9% sodium chloride) (Fre-
senius, Sèvres, France). PBMC were lysed by five cycles ofAvailable online http://ccforum.com/content/13/4/R124
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freezing and thawing, and stored at -80°C until assayed (within
two months).
Detection of circulating NOD2 agonist in human plasma
Human embryonic kidney (HEK) 293T cells (ATCC, Manas-
sas, VA, USA) were cultured in Dulbecco's modified Eagle's
medium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal calf serum (PAA, Pasching, Austria). HEK293T cells
were seeded into 24-well plates at a density of 105 cells/ml
(500 l/well). The detection of NOD2 agonist in biologic fluids
using this transfected cell line has been previously described
[22]. Briefly, HEK293T cells were transfected with a plasmid
permitting the constitutive expression of NOD2 (sensor of
both Gram-positive and Gram-negative PGN) and an NF-B-
dependent reporter gene coding for luciferase. To the trans-
fected cells, 50 l of plasma was added and then incubated
for six hours. The plasma were either from patients or from
healthy volunteers (ICAReB, Institut Pasteur, Paris, France).
The presence of NOD2 agonist in plasma was assessed by
luciferase activity in cell lysates. To the cells, 100 l of lysis
buffer (25 mM Tris-phosphate pH 8, 8 mM MgCl2, 1 mM dithi-
othreitol, 15% glycerol and 1% Triton X-100) was added and
luciferase activity in 10 l of cell extracts was measured in a
microplate luminometer (LB960 luminometer centro, Berthold
Technologies, Germany) after the addition of 100 l of sub-
strate buffer to a final concentration of 1.8 mM luciferin and 1
mM ATP. Luciferase activity was expressed as relative light
unit. In some experiments, a frameshift mutant of NOD2
(fsNOD2) devoid of NF-B activation capacity in response to
NOD2 ligand was used as a negative control (kind gift of Dana
J Philpott, University of Toronto, Toronto, Canada). As positive
controls, we used PGN from Staphylococcus aureus (Invivo-
Gen, San Diego, CA, USA), Escherichia coli (kind gift of Domi-
nique Mengin-Lecreux, Orsay, Paris XI University France), as
well as anaerobic Gram-positive (Clostridium clostridioforme)
and Gram-negative (Bacteroides thetaitamicron) bacterial
PGN (kind gift of Michel Popoff, Institut Pasteur and Domin-
ique Mengin-Lecreux, Orsay, Paris XI University France). In
addition, muramyl dipeptide (MDP), TNF- and IL-1 (R&D
system, Minneapolis, MN, USA) were also tested for compar-
ing the specificity between NOD2 and fsNOD2 transfected
systems. The results from study subjects were presented as
fold change of luciferase activity based on the initial values (T1,
before anesthesia). Detection limit was calculated based on
the mean value ± two standard deviations (SD) of the fold val-
ues at T2 in control subjects. Each test was performed in trip-
licates. A fold increase of 1.57 was considered as positive.
Measurement of endotoxin in peripheral blood 
mononuclear cells (PMBC) and plasma
Detection of bacterial endotoxin in plasma is hindered by the
yellow color of plasma and the presence of inhibitors. We
avoided the background absorbance of plasma by using a
diazo-coupling limulus amebocyte lysate (LAL) assay that
gives a magenta coloration (detection limit: 1.6 pg/ml) (Asso-
ciates of Cape Cod, East Falmouth, MA, USA), and by heating
plasma at 65°C for 30 minutes to inactivate inhibitors as
described [8]. Endotoxins from lysates of PBMC were
assayed with QCL-1000 Chromogenic LAL kit (detection
limit: 5 pg/ml) (Lonza, Walkersville, MN, USA). The assays
were carried out according to the manufacturers' instructions.
Samples were tested in duplicate.
Measurement of cytokines and cortisol
IL-6 and IL-10 were measured in plasma samples by ELISA
(DuoSet, R&D Systems, Minneapolis, MN, USA). Plasma lev-
els of cortisol were measured using an enzyme immunoassay
(AbCys, Paris, France). The assays were carried out according
to the manufacturer's instruction. The color reaction was read
at 450 nm using a MRXELISA microplate reader (DYNEX,
Gaithersburg, PA, USA).
Leukocyte count and measurement of C-reactive protein 
and procalcitonin
Leukocyte counts (per mm3) in whole blood and the measure-
ment of plasma levels of CRP (MODULAR assay, Roche, Mey-
lan, France) and PCT (Kryptor assay, BRAHMS, Clichy,
France) were routinely performed at time points T1, T4, POD1,
and POD2 in the hospital.
Statistical analysis
Data were expressed as median (interquartile range) or mean
± standard error of the mean (SEM), as indicated. The value
zero was assigned to values less than the assay detection
limit. General characteristics of the two surgery groups (AAS
versus CAS) were tested by the Mann-Whitney U test, or
Fischer's exact test depending on the data. Circulating levels
of NOD2 agonist, endotoxin, and inflammatory markers before,
during, and after the surgery of the two groups were examined
by the repeated measure one-way analysis of variance fol-
lowed by the least significant difference method. The relation
between two continuous variables were evaluated using
Spearman's rank correlation tests. P-values less than 0.05
were considered to be significant. All statistical analyses were
performed with SPSS version 12.0 for Windows (Statistical
Package for the Social Science, SPSS, Chicago, IL, USA).
Results
Set-up of the NOD2 agonist detection system
To develop a new tool for the detection of circulating NOD2
agonist, we used the HEK293T cell line constitutively express-
ing NOD2 as a sensor of bacterial PGN through its minimal
motif MDP [20,21]. The cell line was transfected with a luci-
ferase reporter gene under the control of an NF-B-dependent
promoter. This system was able to give positive signals when
simulated with MDP (Figure 1a, left panel) or PGN from S.
aureus (Figure 1a, right panel). The detection system was also
functional when PGN was added to healthy donor's plasma
(Figure 1b). The system efficiently detected various concentra-
tions of PGN from S. aureus (Gram-positive bacteria) or E. coliCritical Care    Vol 13 No 4    Kim et al.
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(Gram-negative bacteria) incubated in plasma from healthy
donors.
Gut flora is mainly composed of anaerobic bacteria, and the
detection of anaerobic bacterial PGN may be more relevant for
bacterial translocation. Thus, we also checked that our system
Figure 1
Detection of circulating peptidoglycan using NOD2 transfected cell line and NF-B-luciferase reporter gene Detection of circulating peptidoglycan using NOD2 transfected cell line and NF-B-luciferase reporter gene. (a) Activation with muramyl dipeptide 
(MDP) or peptidoglycan (PGN) from Staphylococcus aureus (S. aureus). Human embryonic kidney (HEK) 293T cells transfected with nucleotide-
binding oligomerization domain (NOD) 2 and nuclear factor (NF)-B luciferase expression plasmids were stimulated with MDP or S. aureus PGN. 
After six hours of incubation, luciferase activity in cell extracts was measured and expressed as relative light unit (RLU). The figure is the mean ± 
standard error of the mean (SEM) of three independent experiments performed in triplicates. (b) Sensitivity of NOD2-detection of both Gram-nega-
tive and Gram-positive bacterial PGN added in healthy human plasma. HEK293T cells transfected with NOD2 and NF-B luciferase expression 
plasmids were stimulated with various concentrations of PGN from S. aureus or Escherichia coli diluted in plasma from healthy controls. The figure 
is the mean ± SEM of three independent experiments performed in triplicates. (c) NOD2-detection of both purified and non-purified anaerobic 
Gram-negative and Gram-positive bacterial PGN incubated in healthy human plasma. HEK293T cells transfected with NOD2 and NF-B luciferase 
expression plasmids were stimulated with purified or non-purified anaerobic bacterial PGN from Gram-positive (Clostridium clostridioforme) and 
Gram-negative (Bacteroides thetaiotamicron) diluted in plasma from healthy controls. The figure is the mean ± SEM of three independent experi-
ments performed in triplicates. (d) Positive signals in plasma from septic patients. HEK293T cells transfected with NOD2 and NF-B luciferase 
expression plasmids were stimulated with plasma from healthy controls and sepsis patients. As a positive control, MDP was used. The figure is the 
mean ± SEM of three independent experiments performed in triplicates. (e) Specificity of NOD2 detection of bacterial PGN fragment in comparison 
with a frame shift mutant of NOD2 (fsNOD2) transfected system. HEK293T cells, transfected with NOD2 or fsNOD2 and NF-B luciferase expres-
sion plasmids, were stimulated with MDP, TNF- or IL-1. The figure is the mean ± SEM of three independent experiments performed in triplicates. 
(f) Comparison of the signals between NOD2 and fsNOD2 in septic plasma. HEK293T cells transfected with NOD2 or fsNOD2 and NF-B luci-
ferase expression plasmids were stimulated with plasma samples from sepsis patients. The figure is the mean ± SEM of three independent experi-
ments performed in triplicates.Available online http://ccforum.com/content/13/4/R124
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Table 1
Demographic data and information for the operation and postoperative complications of study subjects
Median (min to max), or n (%)
AAS (n = 21) CAS (n = 21) P value
Age (years) 67 (46 to 85) 77 (42 to 88) 0.06
Body weight (kg) 73 (51 to 97) 75 (50 to 95) NS (0.70)
Male 15 (85.7) 18 (71.4) NS (0.45)
Cigarette smoking 20 (95.2) 17 (81) NS (0.34)
Medical history
Coronaropathy 7 (33.3) 5 (23.8) NS (0.50)
Angina pectoris 1 (4.8) 5 (23.8)
Myocardial infarction 2 (9.5) 2 (9.5)
Coronary bypass 1 (4.8) 3 (14.3)
Transluminal angioplasty 2 (9.5) 2 (9.5)
Hypertension 15 (71.4) 18 (85.7) NS (0.45)
Heart failure (left ventricular) 1 (4.8) 2 (9.5) NS (1.00)
Diabetes mellitus 5 (23.8) 5 (23.8) NS (1.00)
Chronic bronchial obstruction 4 (19) 7 (38.1) NS (0.29)
Renal insufficiency 7 (33.3) 8 (38.1) NS (0.75)
Medications
Antiplatelets agents 12 (60) 21 (100) 0.001
Statins 9 (42.9) 15 (71.4) 0.060
Operation information
Blood loss (mL) 1000 (400 to 3500) 100 (50 to 900) < 10-4
Fluid infusion (mL) 4500 (3000 to 9000) 1500 (1000 to 3000) < 10-4
Blood transfusion
Red blood cells 1 (0 to 6) 0 (0 to 2) < 10-4
Fresh frozen plasma 1 (0 to 4) 0 NS (0.15)
Cell-saver 2 (0 to 8) 0 NS (1.00)
Operation duration (hours) 2.5 (1.6 to 6.5) 1.2 (1 to 2.5) < 10-4
Vascular clamping duration (min) 50.5 (14 to 90) 26 (12 to 45) < 10-4
Catecholamines 2 (9.5) 0 0.5
Postoperative complication, n (%) 11 (52.4) 6 (28.0) 0.02
Cardiac complication 6 (28.6) 1 (4.8) NS (0.09)
Respiratory complication 6 (28.6) 1 (4.8) NS (0.09)
Infection 4 (19) 2 (9.5) NS (0.70)
Hemorrhage 1 (4.8) 0 NS (1.00)
Reoperation 3 (14.3) 0 NS (0.23)
Other (pancreatitis, etc) 3 (14.3) 2 (9.5) NS (1.00)
Continuous values were compared by the Mann-Whitney test and frequencies or percentages were tested by the Chi-squared or Fisher's exact 
test.
AAS = abdominal aortic surgery group; CAS = carotid artery surgery; NS = statistically no significance between the two groups.Critical Care    Vol 13 No 4    Kim et al.
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was responsive to the stimulation with purified anaerobic
Gram-positive as well as Gram-negative bacterial PGN incu-
bated in healthy plasma (Figure 1c). NF-B activation was also
obtained with plasma samples from sepsis patients, used as
positive controls, as compared with those from healthy donors
(Figure 1d). The specificity of our system was checked by
transfecting an expression plasmid for fsNOD2, a mutant una-
ble to activate NF-B in response to MDP (Figure 1e).
HEK293T cells express TNF and IL-1 receptors. Accordingly,
NF-B activation in response to TNF or IL-1, turned on the
luciferase gene expression and cells transfected with NOD2
or fsNOD2 were similarly responsive to these inflammatory
cytokines. Plasma samples from sepsis patients (defined
according to Bone and colleagues [33]), showed a positive
signal in the NOD2 transfected system, but did not induce
activation in the fsNOD2-transfected system (Figure 1f). This
latter observation indicates that the putative inflammatory
cytokines present in the plasma of sepsis patients are not in
sufficient amounts to activate the luciferase gene, and that the
NOD2 transfection system can selectively and specifically
detect bacterial NOD2 agonists.
Patients' characteristics
Table 1 presents general characteristics of the study subjects
and information about the operation and postoperative compli-
cations. There was no significant difference in basic character-
istics such as body weight, proportions of gender, cigarette
smoking, and medical history between the two surgery groups,
although CAS patients tended to be older. Medications were
not significantly different between the two groups, except for
the use of anti-platelet aggregation agents. Durations of oper-
ation and vascular clamping were longer in AAS patients than
in CAS patients. The amounts of blood loss and blood trans-
fusion during surgery were also higher in AAS patients, who
had longer durations of mechanical ventilation and hospitaliza-
tion than CAS patients.
Eleven of 21 AAS patients and 6 of 21 CAS patients had post-
operative complications (P = 0.02). Among them, four AAS
patients and three CAS patients were diagnosed as having
infectious complications, but only one of the four AAS patients
was diagnosed within the observational period (at POD2). In
addition, four other AAS patients showed a systemic inflam-
matory response syndrome (SIRS), as defined by Bone and
colleagues [33], at T4 or POD1.
Detection of bacterial NOD2 agonist in plasma samples 
from AAS and CAS patients
Bacterial NOD2 agonist was measured in patients' plasma
samples by the test developed in our laboratory [22]. This in
vitro test was able to detect specifically PGN from Gram-pos-
itive/Gram-negative, aerobic/anaerobic bacteria as shown
above. Figure 2 presents the results for the detection of circu-
lating NOD2 agonist during and after surgery in the two
groups. Values are provided as fold change of luciferase activ-
ity as compared with NF-B activation before anesthesia (T1).
NOD2 agonist was detected in the plasma of 90.5% of AAS
patients, with a peak occurring before aortic clamping (T3).
NOD2 agonist levels were still high after blood reperfusion
(T4), and then gradually declined at POD1 and POD2.
In contrast, no major increase occurred in the plasma of CAS
patients. NOD2 agonist was detected in the plasma of 23.8%
of these patients during surgery, but the levels were signifi-
cantly lower than in AAS patients. One AAS patient, who
developed SIRS at POD1, had very high levels of NOD2 ago-
nist (20 to 40 fold increase of NF-B activation) during the
whole observational period starting at time point T2, which led
to a statistically significant difference in the values between
the two groups at T2. Before surgery, this patient already had
large and numerous calcified atheromas in the aorta and other
arteries throughout the body, which may be responsible for
increased vascular fragility and/or increased ischemia, even
before gut manipulation and clamping. If this patient was
removed from the analysis, there would be no significant differ-
ences between the two groups at time point T2, but there were
still significant differences in NF-B activation between AAS
Figure 2
Assessment of bacterial NOD2 agonist levels in the plasma of AAS and  CAS patients Assessment of bacterial NOD2 agonist levels in the plasma of AAS and 
CAS patients. Human embryonic kidney (HEK) 293T cells transfected 
with nucleotide-binding oligomerization domain (NOD) 2 and nuclear 
factor (NF)-B luciferase expression plasmids were stimulated with 
plasma from abdominal aortic surgery (AAS) and carotid artery surgery 
(CAS) patients. After six hours of incubation, luciferase activity in cell 
extracts was measured, and NF-B activation was calculated as fold 
induction with respect to time point 1 (T1). T1 (before anesthesia), T2 
(before incision), T3 (before clamping), T4 (after blood reperfusion), 
POD1 (postoperative day 1), and POD2 (postoperative day 2). Data 
are shown as median and interquartile range. The two groups were 
compared using analysis of variance repeated measurement and least 
significant difference. P-value (P = 0.003) indicates the significant dif-
ference between the two patient groups in whole study time. * P < 0.05 
and **P < 0.01 are from the comparison of the two groups at each time 
point (Mann-Whitney U test). CAS = white boxes; AAS = grey boxes. 
Black and white circles (T2 to POD2) indicate values within 5th percen-
tile and out of 95th percentile, respectively.Available online http://ccforum.com/content/13/4/R124
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and CAS patients before aortic clamping (T3) and after blood
reperfusion (T4).
Endotoxin levels bound to PBMC and in plasma
The levels of endotoxin in lysates of PBMC are presented in
Figure 3. LPS was detected in PBMC lysates of 71.4% of
AAS patients, with levels significantly higher than in CAS
patients. Highest levels of LPS were observed after blood
reperfusion (T4) in AAS patients and decreased progressively
at POD1 and POD2. On the other hand, the CAS group
showed no significant presence of LPS in their PBMC during
the observational period. Plasma levels of LPS were also
measured in AAS patients. Only 57.1% of the plasmas were
positive and the detected levels were much lower than those
found in PBMC (data not shown).
Comparison of the reliability of the assays for the 
detection of NOD2 agonist and endotoxin
In order to examine the reliability of detection of the NOD2
agonist and endotoxin tests, we compared the positive
responses to the tests based on the detection limits. The
detection limits of the LAL test in PBMC and plasma were 5
pg/ml and 1.6 pg/ml, respectively. The natural structure
derived from PGN following translocation is unknown and may
be different from that resulting from enzymatic digestion and
purification performed in vitro. We avoided extrapolating the
levels of luciferase activity to a standard curve of biochemically
purified PGN. Our test was expressed as fold increase as
compared with the plasma before surgery, each patient being
his own control. The detection limit of the NOD2 agonist test
showed a 1.57-fold increase in luciferase activity as compared
with the value at T1 (before anesthesia). This detection limit
was calculated on the basis of the mean ± 2SD of the fold
increase at T2 in control patients. For reference, the mean ±
SEM and median fold increase for various PGN (5.0 g/ml)
incubated in healthy plasma were 1.76 ± 0.19 and 1.68,
respectively (Figure 1b).
In all AAS and CAS patients, we compared the detection reli-
ability for the NOD2 agonist test in plasma with the endotoxin
test in PBMC. In AAS patients, 90.5% (19 out of 21 patients)
were positive in the NOD2 agonist test, and 71.4% (15 out of
21 patients) were positive in the LAL test (PBMC-associated
LPS). In CAS patients, 23.8% (5 out of 21 patients) were pos-
itive in the NOD2 agonist test, and 19% (4 out of 21 patients)
in the LAL test (Figure 4). From this result, we can conclude
that the NOD2 agonist detection test was more reliable than
the endotoxin test.
Plasma levels of cytokines, CRP, PCT, cortisol and 
leukocyte counts
In order to monitor the inflammatory process, IL-6, IL-10, CRP,
PCT, and cortisol were assayed in plasma and leukocytes
counted at various time points. As shown in Figure 5, signifi-
cantly higher amounts of IL-6 and IL-10 were detected in the
plasma of AAS patients as compared with CAS. IL-6 was
detected in AAS plasma at T4 and the highest value was
attained at POD1. The presence of IL-10 was maximal at T4
and high levels were maintained until POD2. In the CAS
group, IL-10 and IL-6 levels were undetected in most cases.
Plasma levels of CRP were measured at T1, T4, POD1, and
POD2. CRP levels started to increase at POD1 and were fur-
ther increased at POD2 in both groups, but the increments
were significantly higher in AAS patients than in CAS patients
(Figure 5). Similar patterns were also found in PCT levels, with
the difference that the maximal value was reached at POD1
(Figure 5). Similarly, there was a transient increase in leuko-
cyte count at POD1 in AAS patients only, with values going
back to normal at POD2 (data not shown). Plasma cortisol lev-
els were not significantly different between AAS patients (111
± 9 ng/ml) and CAS patients (105 ± 11 ng/ml) at T1. Both
groups of patients showed a significant increase in plasma lev-
els of cortisol at POD1 (AAS: 229 ± 44 ng/ml and CAS: 157
± 26 ng/ml), with a tendency towards higher values for AAS
patients (P = 0.07).
Correlation between the levels of circulating NOD2 
agonist and other parameters
The survey indicated that the inflammatory response took
place after bacterial NOD2 agonist translocation. Among AAS
Figure 3
Assessment of endotoxin (LPS) associated with circulating peripheral  blood mononuclear cells (PBMC) in AAS and CAS patients Assessment of endotoxin (LPS) associated with circulating peripheral 
blood mononuclear cells (PBMC) in AAS and CAS patients. Endotoxin 
associated with patients' PBMC was measured using a Limulus ame-
bocyte assay. T1 (before anesthesia), T2 (before incision), T3 (before 
clamping), T4 (after blood reperfusion), POD1 (postoperative day 1), 
and POD2 (postoperative day 2). Data are shown as median and inter-
quartile range. The two groups were compared using analysis of vari-
ance repeated measurement and least significant difference. P-value (P 
= 0.006) indicates the significant difference between the two patient 
groups in whole time measured. * P < 0.05 are from the comparison of 
the two groups at each time point (Mann-Whitney U test). CAS = 
carotid artery surgery (white boxes); AAS = abdominal aortic surgery 
(grey boxes). Black and white circles (T1 to POD2) indicate values 
within 5th percentile and out of 95th percentile, respectively.Critical Care    Vol 13 No 4    Kim et al.
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patients, levels of circulating NOD2 agonist at T4 positively
correlated with those of IL-10 at T4 and of cortisol at POD1 (r
= 0.46, P = 0.04; and r = 0.55, P = 0.01, respectively). Inter-
estingly, in AAS patients but not in CAS patients, cortisol lev-
els at POD1 correlated with those of IL-10 at T4 and of PCT at
POD1 (r = 0.59, P = 0.006; and r = 0.55, P = 0.02, respec-
tively), and with the length of clamping (r = 0.45, P = 0.05). In
AAS patients, the length of clamping correlated with levels of
IL-6 at T4 and of PCT at POD1 (r = 0.53, P = 0.03; and r =
0.52,  P  = 0.02, respectively). There was no correlation
between the length of clamping and levels of NOD2 agonist in
the plasma. This is consistent with the results of Figure 2,
showing that NOD2 agonist translocation occurred as soon as
the gut was manipulated and reclinated by the surgeon, and
thus before vascular clamping.
Discussion
Derangement in gut barrier function occurs in many clinical
settings. Endotoxin translocation has been evidenced in some
cases and more frequently than in systemic bacterial translo-
cation. Still, endotoxin is only representative of Gram-negative
bacteria, microbial translocation may occur more regularly
than previously reported after endotoxin measurement. The
aim of this study was: to develop a tool allowing us to measure
PGN, representative of both Gram-negative and Gram-posi-
tive; to address its presence within the bloodstream of
patients in a clinical situation known to favor translocation of
microbial products; to perform a survey during and after sur-
gery to assess the frequency of the translocation of microbial
products; and to attempt linking PGN translocation with the
inflammatory process.
AAS is thought to be associated with endotoxin and bacterial
translocation through the gut barrier, following manipulation of
the gut by the surgeon and aortic clamping. However, evi-
dence to prove this link was difficult to gather, probably
because bacteria translocated into the bloodstream are rap-
idly killed and do not give rise to positive hemocultures
[30,34]. Several studies, including ours, aimed to address this
question by measuring circulating endotoxin [8,9]. However,
this approach is hindered by the presence of many interfering
or blocking molecules (soluble CD14, LPS-binding protein,
lipoproteins) [15,16,35]. Thus the determination of LPS levels
in the plasma of patients after surgery was not reliable enough,
and did not allow for the demonstration that translocation was
taking place systematically.
In the present study, we set up a new method for detecting
bacterial NOD2 agonist in plasma, using a cell line transfected
with NOD2, a general sensor of PGN through its minimal motif
MDP [20,21], and a reporter gene under the control of the NF-
B transcription factor. Measurement of PGN is relevant in
many aspects. First, it is the major component of Gram-posi-
tive bacteria and is also found in Gram-negative bacteria.
Thus, when LPS detection addresses only Gram-negative
bacteria, PGN detection addresses both types. Second, we
showed that our system efficiently detected anaerobic bacte-
rial PGN, expected to be more representative of the intestinal
flora. Finally, the specificity of our test was confirmed by the
use of a frameshift mutant of NOD2, which cannot be acti-
vated by bacterial PGN or its fragment [20,21]. This system
showed that translocation of pathogen-associated molecular
patterns (PAMPs) occurred in abdominal aortic surgery with a
frequency higher than that measured so far, and that the assay
of NOD2 agonist in plasma is a useful and sensitive tool for
early detection of a bacterial product in the bloodstream. As
the exact nature of circulating PGN is unknown, we used the
terms 'NOD2 agonist' to name the circulating PAMP found in
patients' plasma. The circulating bacterial material is probably
closer to PGN than MDP. Indeed, in the HEK239T test, simi-
larly to biochemically purified PGN, plasma samples led to a
positive signal when added after the transfection step, in con-
trast to MDP, which had to be added in the presence of the
transfection reagent in order to be detected. This is the first
time that the NOD2 agonist was measured and found in AAS
patients. Its detection is more reliable than that of LPS. Our
results concur with those of a study of hemorrhagic shock in
rat, showing that 30% had detectable amounts of LPS, but
73% were positive for circulating NOD2 agonist [30].
On the other hand, CAS patients (our negative control) did not
show peaks for circulating NOD2 agonist or endotoxin, and
had a relatively lower inflammatory response after the surgery,
even if in some rare cases NOD2 agonist was detected in their
Figure 4
Reliability of the tests for circulating NOD2 agonist in plasma and  endotoxin in plasma and associated with PBMC Reliability of the tests for circulating NOD2 agonist in plasma and 
endotoxin in plasma and associated with PBMC. The figure indicates 
the percentage (%) of positive patients based on the detection limits of 
the tests. AAS = abdominal aortic surgery; CAS = carotid artery sur-
gery; NOD = nucleotide-binding oligomerization domain; PBMC = 
peripheral blood mononuclear cells; PGN = peptidoglycan.Available online http://ccforum.com/content/13/4/R124
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plasma. Of course the CAS group underwent a shorter and
less severe insult (shorter duration of surgery, less blood loss,
rare blood transfusion), which may account for the lower
inflammatory response on POD1 and POD2. Nevertheless,
CAS patients were relevant as a control group for AAS
patients. The groups were comparable in terms of weight, sex
ratio, and pathology prior to surgery (atherosclerosis, diabe-
tes, smoking habits). They were also undergoing vascular sur-
gery, but without intestinal manipulation for CAS patients. We
concluded that bacterial translocation is indeed tightly linked
to reclination of the gut during surgery, in agreement with our
previous observation [9]. Indeed, laparatomy and handing are
sufficient to induce degradation in the intestinal brush border
membrane [36].
Regarding medications, especially for statins, the CAS
patients were higher consumers than AAS patients, although
the difference was not statistically significant. Statins are
known to have pleiotropic effects such as a reduction in inflam-
matory response, stabilization of atheroscleortic plaques, and
improvement in vascular endothelial function, as well as a lipid
lowering effect [37-39]. In our study, statin use had no signifi-
cant effect on the levels of NOD2 agonist and inflammatory
markers in either group. These observations suggest that dif-
ferences in inflammatory response or circulating NOD2 ago-
nist between the two surgery groups during the observational
period were not related to statin use.
As expected, levels of inflammatory markers were higher in
AAS than in CAS patients. In AAS patients, all endogenous
markers of inflammation increased after circulating NOD2
agonist appeared. From these results, we assumed that bac-
terial translocation, which occurs before aortic clamping fol-
lowing abdomen incision and gut manipulation, may also
contribute to a systemic inflammatory response in AAS
patients. As illustrated by some correlations between NOD2
agonist and inflammatory markers (cortisol, IL-10), the pres-
ence of circulating NOD2 agonist contributes to the inflamma-
tory response that was associated with a higher number of
postoperative complications in AAS patients. Indeed, levels of
Figure 5
Plasma levels of IL-10, IL-6, C-reactive protein and procalciton in in AAS and CAS patients Plasma levels of IL-10, IL-6, C-reactive protein and procalciton in in AAS and CAS patients. Plasma levels of cytokines, C-reactive protein (CRP), 
and procalcitonin (PCT) were measured at T1 (before anesthesia), T2 (before incision), T3 (before clamping), T4 (after blood reperfusion), POD1 
(postoperative day 1), and POD2 (postoperative day 2). Data are shown as median and interquartile range. The two groups were compared using 
analysis of variance repeated measurement and least significant difference. P-values indicate the significant difference between the two patient 
groups at all times measured. * P < 0.05, **P < 0.01 and ***P < 0.001 are from the comparison of the two groups at each time point (Mann-Whitney 
U test). CAS = carotid artery surgery (white boxes); AAS = abdominal aortic surgery (grey boxes).Critical Care    Vol 13 No 4    Kim et al.
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IL-10 and cortisol are known to correlate with disease severity
[8,40,41]. Furthermore, it is worth mentioning that PGN and
PGN-derived structures are known to prime cells and enhance
a further response to LPS [42], to synergize with cytokines
[43], TREM-1 ligand [44], and other PAMPs [45] to favor
inflammation, and to induce shock and organ dysfunction in
vivo [46,47].
Conclusions
In numerous clinical settings, microbial products derived from
the gut are thought to worsen the disease. However, systemic
bacterial translocation was rarely proven and rather endotoxin
translocation has been measured. Endotoxins are only derived
from Gram-negative bacteria and measuring PGN, which
derives from both Gram-negative and Gram-positive bacteria
could be more accurate. We report that in patients undergoing
abdominal aortic surgery, most patients were positive for cir-
culating NOD2 agonist, indicating that microbial translocation
can be more frequent than previously thought when circulating
endotoxin was measured. Furthermore, our data suggest that
the presence of NOD2 agonist also contributes to the inflam-
matory response. Although the present test remains time con-
suming, we expect in the near future to develop a stable
permanent transfected cell line that would allow us to perform
the test within six hours. Furthermore, our results suggest that
any other strategies that would be aimed to recognize the
presence of PGN-like structure could be very useful.
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